Posted on 24/03/2010 in Animal Health Supplier News Novartis Animal Health is to move ahead with the development of a potentially promising new cancer treatment platform with partner Morphogenesis.
As part of an exclusive worldwide co-development and commercialisation agreement signed late last year, the firms are to create a number of cancer vaccines for dogs, while Novartis will also gain the rights to Morphogenesis' canine and feline cancer cell lines.
The two companies are set to work together closely to bring these products to market, with Morphogenesis due to receive a number of milestone payments based on the developmental and commercial progress of the drugs.
Dr Patricia Lawman, chief executive officer of Morphogenesis, stated that the partnership represents a "new chapter" in the treatment of canine cancer.
She added: "We share the common objective of finding treatments for serious animal diseases where there exist significant unmet needs."
Last week, Novartis Animal Health launched its new sheep drench product Zolvix in the UK, which is designed to help combat harmful parasites.Other news stories from 24/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
